Clinical trial • Phase I • Oncology
AB521 for Solid Tumors|Clear cell renal cell carcinoma
Phase I trial of AB521 for Solid Tumors|Clear cell renal cell carcinoma. 282 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Solid Tumors|Clear cell renal cell carcinoma
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 28-02-2025
- First CTIS Authorization Date
- 27-05-2025
Trial design
Phase I trial across 1 site in Spain.
- Target Sample Size
- 282
Eligibility
Recruits 282 Vulnerable population selected (isVulnerablePopulationSelected: true). No further details on vulnerable population considerations, consent or assent handling provided in the available data..
- Vulnerable Population
- Vulnerable population selected (isVulnerablePopulationSelected: true). No further details on vulnerable population considerations, consent or assent handling provided in the available data.
Recruitment
- Planned Sample Size
- 282
- Recruitment Window Months
- 25
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 282
Spain
- Earliest CTIS Part Ii Submission Date
- 19-05-2025
- Latest Decision Or Authorization Date
- 08-05-2026
- Processing Time Days
- 354
- Number Of Sites
- 1
- Number Of Participants
- 7
Sites
- Site Name
- Hospital Universitari Vall D Hebron
- Department Name
- Medical Oncologist
- Contact Person Name
- Cristina Suarez Rodriguez
- Contact Person Email
- csuarez@vhio.net
- Number Of Participants
- 7
Sponsor
Primary sponsor
- Full Name
- Arcus Biosciences Inc.
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Investigational products
- Investigational Product Name
- AB521
- Combination Treatment
- Yes
Related trials
Other published trials that may interest you.
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer
- Pembrolizumab for Classical Hodgkin lymphoma | Melanoma | Solid tumours (MSI-H/dMMR) | Solid tumours (TMB-H)